Aspirin Reduces Cerebrovascular Events in DM
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We undertook the Japanese primary prevention of atherosclerosis with aspirin for diabetes (JPAD) trial to examine the efficacy of low-dose aspirin therapy for the primary prevention of atherosclerotic events in type 2 diabetic patients. 18 Unfortunately, a clear benefit for aspirin in the primary prevention of major cardiovascular events in patients with diabetes remains to be elucidated. Therefore, we sought to investigate whether aspirin therapy was effective for diabetic patients with higher BP level.
Methods
The JPAD trial design and overall findings have been reported previously. 18 Written informed consent was given by each patient. The study protocol was in agreement with the guidelines of the ethics committees at the participating institutions and the study complied with the Declaration of Helsinki. Briefly, this multicenter, prospective, randomized, open, blinded endpoint study conducted at 163 institutions throughout Japan enrolled 2,539 patients with type 2 DM, without a history of atherosclerotic disease. The institutional review board at each participating hospital approved this trial, and written informed consent was given by each patient. In the JPAD trial, the inclusion criteria were diagnosis of type 2 DM, age between 30 and 85 years, and ability to provide informed consent. The exclusion criteria were electrocardiographic ischemic changes; a history of coronary heart disease, cerebrovascular disease, or arteriosclerotic disease; atrial fibrillation; use of antiplatelet or antithrombotic therapy; a history of severe gastric or duodenal ulcer. 18 In total, 2,539 patients were randomly assigned as follows: 1,262 patients in the aspirin group, and 1,277 patients in the non-aspirin group. The median follow-up period was 4.37 years.
In this subanalysis, we divided the JPAD participants according to their BP at enrollment (systolic BP (SBP) ≥140 mmHg and/or diastolic BP (DBP) ≥90 mmHg: unattained group; SBP <140 mmHg and DBP <90 mmHg: attained group). The unattained group consisted of 1,022 patients and the attained group consisted of 1,517 patients. We conducted atherosclerotic events analyses and subgroup analyses of atherosclerotic events: cerebrovascular events, including stroke and transient ischemic attack (TIA); coronary events, including MI and angina; and, aortic and peripheral vascular events. 
Definition of Atherosclerotic Events
The primary endpoint was any atherosclerotic event, which was a composite of sudden death; death from coronary, cerebrovascular or aortic cause; nonfatal acute MI; unstable angina; newly developed exertional angina; nonfatal ischemic and hemorrhagic stroke; TIA; or nonfatal aortic and peripheral vascular disease (arteriosclerosis obliterans, aortic dissection, mesenteric arterial thrombosis) during the follow-up period. All potential endpoints were adjudicated by an independent committee on validation of data and events that was unaware of the group assignments.
Presentation of Hemoglobin A1c Level
Hemoglobin A1c values were converted from the Japanese Diabetes Society (JDS) values used in the main analysis of the JPAD trial into National Glycoprotein Standardization Program (NGSP) equivalent values. NGSP equivalent values were calculated using the following formula: NGSP equivalent value (%)=JDS value (%)+0.4%. 19
Statistical Analysis
Efficacy comparisons were performed on the basis of time to the first event, according to the intention-to-treat principle, including all patients in each group to which they were randomized with patients lost to follow-up cut from the study as of their last hospital visit. Following the descriptive statistics, cumulative incidences of primary endpoints were estimated using the Kaplan-Meier method and differences between groups were then assessed with the log-rank test. The chi-square test was used to compare the frequency data between the groups. We used the Cox proportional hazards analysis to estimate hazards ratios (HRs) of BP level (SBP ≥140 mmHg and/or DBP ≥90 mmHg), with 95% confidence interval (CI). We included aspirin, and the clinically important factor such as age and sex and the significant factors in the characteristics such as BP, body mass index (BMI), dyslipidemia, proteinuria, and use of α-glucosidase inhibitors. We excluded the significant factors in the characteristics such as nephropathy and use of antihypertensive agents. Because nephropathy was almost synonymous with proteinuria, nephropathy was excluded from the Cox proportional hazards analysis. Because it was natural that there was a significant difference in the use of antihypertensive agents, their use was excluded. Patients with missing values for any selected variable were excluded from the analyses that used that variable. All statistical analyses were conducted using SAS software Version 9.1 (SAS Institute Inc, Cary, NC, USA). P-values <0.05 were considered statistically significant.
Results
Baseline Clinical Characteristics
The baseline clinical patient characteristics are shown in Table 1 . Mean BP was 149/82 mmHg in the unattained group and 126/73 mmHg in the attained group. There were significant differences in age, sex, BP, BMI, the frequency of dyslipidemia, proteinuria, and use of α-glucosidase inhibitors between the unattained and attained groups. The clinical characteristics, such as the frequency of smoking, diabetic retinopathy, diabetic neuropathy, duration of DM, use of statins, and use of drugs for DM except for the usage of α-glucosidase inhibitor, were all similar between groups. DM was similarly controlled between the groups; mean (SD) levels of hemoglobin A1c (NGSP) were 7.5 (1.3) % in the unattained group, and 7.5 (1.3) % in the attained group.
Higher BP as a Risk for Atherosclerotic Events in DM
A total of 154 atherosclerotic events occurred. The incidence of the primary endpoint of an atherosclerotic event was significantly higher in the unattained group (20.1 cases per 1,000 person-years) than in the attained group (12.2 cases per 1,000 person-years) (HR, 1.65; 95%CI, 1.20-2.27; log-rank test, P=0.0016, Figure 1 ).
Subgroup Analyses of Cerebrovascular Events, Coronary Events, and Aortic and Peripheral Vascular Events
The atherosclerotic events are shown in Table 2 . The incidence rate of cerebrovascular events was significantly higher in the unattained group (43 events, 4.2%) than in the attained group (30 events, 2.0%) (HR, 2.18; 95%CI, 1.37-3.51; log- Comparison of primary endpoints of atherosclerotic events in the unattained and attained groups. The incidence of the primary endpoint of an atherosclerotic event was significantly higher in the unattained group than in the attained group. Aspirin Reduces Cerebrovascular Events in DM rank test, P=0.0008, Figure 2 ). Ischemic stroke happened in 36 in the unattained group and in 24 in the attained group, and hemorrhagic stroke happened in 7 in the unattained group and in 6 in the attained group. The incidence rate of ischemic stroke events was also significantly higher in the unattained group than in the attained group (HR, 2.28; 95%CI, 1.37-3.87; log-rank test, P=0.0013). The incidence rate of aortic and peripheral vascular events was also significantly higher in the unattained group (1.2%) than in the attained group (0.4%, Table 2 ). There were no significant differences, however, in the incidence rate of coronary events between the unattained group (2.4%) and the attained group (2.5%, Table 2 ).
Effect of Aspirin Therapy on the Incidence of Cerebrovascular Events
We performed analyses of patients receiving aspirin therapy and those who were not. The incidence of cerebrovascular events was significantly higher in the unattained group (5.2%) than in the attained group (1.9%) (HR, 2.84; 95%CI, 1.52-5.52; log-rank test, P=0.0008, Figure 3 Upper) in patients not receiving aspirin therapy; however, the incidence rate of cerebrovascular events in the unattained group (3.3%) was as low as the incidence in the attained group (2.1%) (HR, 1.64; 95%CI, 0.83-3.29; log-rank test, P=0.15, Figure 3 Lower) in patients receiving aspirin therapy. We compared the incidence of cerebrovascular events between patients receiving aspirin therapy and those without aspirin therapy in the unattained group, and the result was not significant. Though there were significant differences in several clinical characteristics between the unattained group and the attained group, Cox proportional hazards analysis revealed that BP control, age, and proteinuria were independent predictive factors for cerebrovascular events in type 2 diabetic patients ( Table 3) .
Safety
The analysis of bleeding events is shown in Table 4 . In the unattained and attained groups, there were 7 patients and 9 patients, respectively, with gastrointestinal bleeding. In the unattained group, 2 patients had serious adverse events that necessitated transfusions; 2 patients in the attained group also required transfusions. In the unattained and attained groups, there were 3 patients and 10 patients with retinal hemorrhages. In the unattained group, 7 patients had hemorrhagic strokes; 6 patients in the attained group had hemorrhagic strokes. Overall, there was no significant difference in the rate of hemorrhagic events between the unattained group and the attained group.
Discussion
In the present study, the incidence of primary atherosclerotic events in type 2 diabetic patients, consisting of cerebrovascular events, coronary events, and aortic or peripheral vascular events, was significantly higher in the unattained group than in the attained group. It indicates that BP control influences the incidence of primary atherosclerotic events in diabetic patients. Recently, the Antithrombotic Trialists' Collaboration under- Figure 2 . Comparison of cerebrovascular events in the unattained and attained groups. The incidence of cerebrovascular events was significantly higher in the unattained group than in the attained group. Comparison of cerebrovascular events in the unattained and attained groups without aspirin therapy. The incidence rate of cerebrovascular events was significantly higher in the unattained group than in the attained group in patients not receiving aspirin therapy. (Lower) Comparison of cerebrovascular events in the unattained and attained groups with aspirin therapy. The incidence rate of the cerebrovascular events in the unattained group decreased to the level of incidence in the attained group in patients receiving aspirin therapy. took a meta-analysis that compared long-term aspirin use vs. a non-aspirin control. The meta-analysis results reported that in the primary prevention trials, aspirin therapy yielded a 12% proportional reduction in serious vascular events. 20 However, that study included a small number of diabetic patients, so the data do not support the effect of aspirin therapy in the primary prevention of major cardiovascular events in patients with DM. In the present study, the incidence of cerebrovascular events was significantly higher in the unattained group than in the attained group. Cox proportional hazards analysis revealed that higher BP is an independent predictive factor for cerebrovascular events in type 2 diabetic patients. Although the incidence of cerebrovascular events was significantly higher in the unattained group than in the attained group in patients without aspirin therapy, the incidence of cerebrovascular events in the unattained group was as low as the incidence in the attained group in patients with aspirin therapy. Furthermore, aspirin therapy reduces ischemic stroke events without an increase in hemorrhagic stroke events. This data may indicate that aspirin therapy reduces the incidence of cerebrovascular events effectively in patients with higher BP than in those with controlled BP. However, Cox proportional hazards analysis showed that aspirin is not an independent predictive factor for cerebrovascular events. Furthermore, there was no significant difference in the incidence of cerebrovascular events between patients receiving aspirin therapy and those without aspirin therapy in the unattained group. Therefore, the present study shows the possibility that aspirin reduces cerebrovascular event in diabetic patients with higher BP. We may need a more appropriate control group to confirm the significance of aspirin therapy.
The incidence of aortic and peripheral vascular events was significantly lower in the attained group than in the unattained group; however, there was no significant difference between the 2 groups in any of the following diseases: arteriosclerosis obliterans; aortic dissection; mesenteric artery thrombosis or retinal artery thrombosis. There are few reports that describe the association between aortic and peripheral vascular events and aspirin therapy in diabetic patients. In the PPP Trial, 21 the effects of aspirin for patients with peripheral artery disease were not significant in non-diabetic patients; furthermore, aspirin therapy did not show any significant preventive effect for cardiovascular events in asymptomatic patients with lower ankle-brachial pressure indexes in the POPADAD Trial 17 or the Aspirin for Asymptomatic Atherosclerosis Trial. 22 In the present study, the effect of aspirin seems to be not proven, based on these data, even if there are a lot of peripheral vascular patients.
As regards the incidence of coronary events, there were no significant differences between the unattained group and the attained group; however, the incidence of MI was higher in the unattained group than in the attained group. In the HOT study, the MI rate between the high BP and low BP groups was of borderline significance. 23 Thus, the influence of higher BP on the incidence of coronary events seems to be stronger in the case of serious coronary events than for all coronary events.
Study Limitations
This subanalysis has a few limitations in addition to those reported in the JPAD Study. 18 The JPAD trial did not achieved the planned statistical power because of the lower than expected incidence of atherosclerotic events. Because the present study was a subanalysis of the JPAD trial, the number of patients and number of events was lower than in the main study. Therefore, the present study is much more underpowered for observing the effects of aspirin in the select subgroups. Because of the nature of making several subgroups, significant results should be interpreted with the caution of potential α error. Thus, a new trial that sets diabetic patients with unattained BP as the main object is needed.
Conclusions
This study indicates that BP level influences the incidence of cerebrovascular events in diabetic patients. In the primary prevention of cerebrovascular events, aspirin therapy might have significant effects in diabetic patients with SBP ≥140 mmHg and/or DBP ≥90 mmHg, though BP control is more important for preventing cerebrovascular events. 
Other bleeding events
Hemorrhagic stroke 7 6 Retinal bleeding 3 10
Bleeding after tooth extraction 0 1
Subcutaneous hemorrhage 1 3 Hematuria 1 2
Nose bleeding 3 4
Chronic subdural hematoma 2 0 SOEJIMA H et al.
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